SSG
PCVX icon

Summit Securities Group’s Vaxcyte PCVX Stock Holding History

Summit Securities Group’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,779
Closed -$90.3K – 1280
2025
Q2 		$90.3K Buy
+2,779
New +$91.1K 0.02% 379

Other funds holding PCVX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return

Summit Securities Group's PCVX Position: Q3 2025 in Review

Summit Securities Group sold out of Vaxcyte (PCVX) in Q3 2025, closing a stake of 2,779 shares — an estimated $90.3K sold.

Summit Securities Group first reported a position in PCVX in Q2 2025 and held it in 1 quarter. The position peaked at $90.3K in Q2 2025. 285 funds tracked by Wall St. Rank hold PCVX as of Q3 2025.

  • Summit Securities Group reported no remaining Vaxcyte position as of Q3 2025 after selling out during the quarter.
  • Summit Securities Group sold 2,779 Vaxcyte shares in Q3 2025, an estimated $90.3K.
  • Summit Securities Group first reported a position in Vaxcyte in Q2 2025 and held it in 1 quarter.
  • Summit Securities Group's Vaxcyte position peaked at $90.3K in Q2 2025.
  • 285 funds tracked by Wall St. Rank held Vaxcyte as of Q3 2025.

Based on Summit Securities Group's 13F filing for Q3 2025, filed 13 Nov 2025.